Navy

Adenoviral vector-based malaria vaccines

  • US Patent No. 9254316
  • Issued: February 09, 2016
  • Status: Active
Medical & Biotechnology

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.

Do you have questions or need more information on a specific technology? Let's talk.

Contact Us